September 4, 2019 | Press Releases

Vensana Capital Launches with Inaugural $225 Million Fund

21

Novel FDA PMA & de novo 510k approvals

60

U.S. Commercial Product Launches

39

Level I Clinical Trials

31

Strategic Financings

31

Exits by IPO or M&A